# Source:Dr. John Campbell, URL:https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg, language:en-UK

## Give thanks COVID safely
 - [https://www.youtube.com/watch?v=dt-RHHOMl2g](https://www.youtube.com/watch?v=dt-RHHOMl2g)
 - RSS feed: https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg
 - date published: 2020-11-25 00:00:00+00:00

US Influenza

United States

Deaths, logged nearly 2,092

Highest since 6th May, (2,611)

Record numbers of fatalities

Maine, Alaska, Missouri, North Dakota, Indiana, Wisconsin, Washington, Ohio, Oregon 

Dr. Fauci

https://www.washingtonpost.com/politics/thanksgiving-covid-decisions/2020/11/24/1fa6aba4-2b72-11eb-8fa2-06e7cbb145c0_story.html


We had a great Thanksgiving last year and we’re looking forward to a great Thanksgiving next year, but today we’re going to call a timeout

Marist poll

http://maristpoll.marist.edu/marist-poll-results-analysis/#sthash.iGKNGTzM.PHNgfmUD.dpbs

58% plan on celebrating Thanksgiving with fewer people

36% plan same number of people as last year

4% more people

Who will have smaller gatherings

Democrats, 74%

Independents, 58%

Republicans, 39%

Midwest, 65%

Northeast, 63%

West, 57%

South, 51%

Personal pandemic

71% of adults know someone who has had coronavirus

Travel

https://www.washingtonpost.com/nation/2020/11/25/coronavirus-covid-live-updates-us/

Thanksgiving travel down?

AAA estimates a 10% reduction in travel

6.4 million doses in 24 hours

https://www.washingtonpost.com/health/2020/11/24/vaccine-plan-first-doses/

State allocation, which based overall population

20 million people in 2020

Pfizer, larger centers first

Vaccine priorities?

Health-care workers

Residents of long-term care facilities

First responders

Teachers

Grocery workers

100 million high-risk

53 million adults over the age of 65

US Problems, next months

Winter

State, county, municipality

Coordination, UK, US, Germany

I woke up in a free country

Testing accuracy, and may not be positive for days

Everyone tested every 2 weeks

Contact tracing is weak, 100 people per infection need contacted

100,000 contact tracers needed

Compliance when pinged

Lack of therapeutics

Participation in clinical trials

Vaccine immunity delay, IgG could be several weeks

Anti-vaccine thinking 

Vitamin D denial

UK Christmas

https://www.bbc.co.uk/news/explainers-55056375

Between 23 and 27 December

Three households, allowed to form a fixed temporary "Christmas bubble"

Mix indoors and stay overnight

Northern Ireland, 22 to 28 December

England, existing support bubble counts as one household

No limit to the number of people in a household joining a bubble

People self-isolating should not join a bubble

Any positives or symptomatics within 48 hours, all have to self-isolate

Travel restrictions will be lifted, visit families anywhere in the UK

No extra public transport


Scotland, relaxation of restrictions will not be extended to cover New Year's Eve


Care home residents, not to join bubbles


France

Emmanuel Macron, restrictions remain in coming weeks

Continue to stay at home

Telecommute

Give up private meetings and family gatherings

All nonessential travel

Christmas Eve and New Year’s Eve, share these moments together among family

Half dose of Oxford vaccine

https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-oxford/decades-of-work-and-half-a-dose-of-fortune-drove-oxford-vaccine-success-idUKKBN2832NG

Adenovirus “viral vector”

Flu, MERS and Ebola not yet at phase 3

Fatigue, headaches or arm aches were milder than expected

Half first dose

Second, full dose booster shot at the scheduled time

90% verses 62%

## Australia Update
 - [https://www.youtube.com/watch?v=L5DojKdL5dw](https://www.youtube.com/watch?v=L5DojKdL5dw)
 - RSS feed: https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg
 - date published: 2020-11-24 00:00:00+00:00

Life is essentially back to normal in Australia, Mr. David Davies reports from Australia

AgUnity main link
https://www.agunity.com

AgUnity is an Australian tech-for-good start-up empowering thousands of organizations working towards the UN Sustainable Development Goals to better connect with the last mile. By enabling trust, increasing transparency, giving access to market and limiting corruption through blockchain technology, AgUnity provides smallholder farmers a platform that is relevant and useful for them, essentially empowering them to lift themselves out of poverty. For more info, visit www.agunity.com or contact them via hello@agunity.com.

## Australia and the world
 - [https://www.youtube.com/watch?v=eVTPtM6LzqU](https://www.youtube.com/watch?v=eVTPtM6LzqU)
 - RSS feed: https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg
 - date published: 2020-11-24 00:00:00+00:00

Mr David Davies highlights some essential principles for a sustainable future, illustrated through his AgUnity work.

AgUnity is an Australian tech-for-good start-up empowering thousands of organizations working towards the UN Sustainable Development Goals to better connect with the last mile. By enabling trust, increasing transparency, giving access to market and limiting corruption through blockchain technology, AgUnity provides smallholder farmers a platform that is relevant and useful for them, essentially empowering them to lift themselves out of poverty. For more info, visit www.agunity.com or contact them via hello@agunity.com.

AgUnity resources, https://agunity.sharepoint.com/sites/agunityexternalshare/Shared%20Documents/Forms/AllItems.aspx?id=%2Fsites%2Fagunityexternalshare%2FShared%20Documents%2F00%20AgUnity%20Media%20for%20External%20Parties%2F01%20Field%20Footage%20for%20Dr%20Campbell&p=true&originalPath=aHR0cHM6Ly9hZ3VuaXR5LnNoYXJlcG9pbnQuY29tLzpmOi9zL2FndW5pdHlleHRlcm5hbHNoYXJlL0VxVzlxMkRkT2ZaSmdBUVZEUDF0UUg0QnVvWlNJS0JFVU1hcnZZOF85VkVkcHc_cnRpbWU9TVJNeng2T1EyRWc

## Oxford vaccine, looking very good
 - [https://www.youtube.com/watch?v=wAvnAkAMmmM](https://www.youtube.com/watch?v=wAvnAkAMmmM)
 - RSS feed: https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg
 - date published: 2020-11-24 00:00:00+00:00

US Influenza
Oxford / AstraZeneca 

Phase 2 / 3

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext


(23rd November)

https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html

Viral vector, weakened version, chimpanzee, common cold adenovirus

After vaccination, the surface spike protein is produced

Antibodies

T cells
Interim report, 131 confirmed infections
Positive high-level results
8,000 swabs per week
Therefore picking up asymptomatics
Clinical trials of AZD1222
UK and Brazil data only
Vaccine was highly effective in preventing COVID-19
No hospitalisations or severe cases of the disease were reported in participants receiving the vaccine
Group one, n = 2,741
AZD1222 was given as a half dose
Followed by a full dose
At least one month apart
Vaccine efficacy of 90%
Group 2, n = 8,895
Two full doses at least one month apart
Vaccine efficacy 62 %
Combined analysis from both dosing regimens, n = 11,636
An average efficacy of 70%
All results were statistically significant (p less than  = 0.0001)
One in 10,000
More data will continue to accumulate
Refining the efficacy reading 
Establishing the duration of protection.
Independent Data Safety Monitoring Board
Met its primary endpoint
Protection from COVID-19 occurring 14 days or more after receiving two doses
No serious safety events related to the vaccine have been confirmed
AZD1222 was well tolerated across both dosing regimens
AstraZeneca immediately prepare regulatory submission
Early approval
Emergency Use Listing from the World Health Organization
For an accelerated pathway to low-income countries
Full analysis of the interim results is being submitted for peer-reviewed journal
Professor Andrew Pollard
These  findings  show  that  we  have  an  effective  vaccine  that  will  save  many  lives
Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, 
more people could be vaccinated with planned vaccine supply
Pascal Soriot, Chief Executive Officer
Simple supply chain
no-profit pledge
commitment to broad, equitable and timely access means
it will be affordable and globally available
supplying hundreds of millions of doses on approval
Control group
Meningococcal conjugate vaccine called MenACWY
or saline
Participants 
Aged 18 years or over
Diverse racial and geographic groups
Healthy or have stable underlying medical conditions
Clinical trials are also being conducted in
US, Japan, Russia, South Africa, Kenya, Latin America
Planned trials in other European and Asian countries
N = 60,000
Manufacturing capacity
3 billion doses in 2021
Storage / transport
2-8 degrees Celsius
36-46 degrees Fahrenheit
For at least six months
Administered within existing healthcare settings
COV002
A single-blinded, multi-centre, randomised, controlled Phase II/III trial
Assessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK
Aged 18 years or over
Healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus
Group one
One or two intramuscular doses of a half dose (~2.5 x1010 viral particles)
Comparator, meningococcal vaccine MenACWY.
Group two 
Full dose (~5x1010 viral particles)
Comparator, meningococcal vaccine MenACWY.
Clinical assessments for safety as well as immunogenicity
Multiple timepoints
For a year
Weekly swabbing for viral presence
COV003
COV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial in Brazil
Two intramuscular doses of a full dose (~5x1010 viral particles) of AZD1222 or comparator
Meningococcal vaccine MenACWY as first dose and a saline placebo as second dose
UK, Oxford / Astrazeneca 
The UK has ordered 100m doses
US also
UK government has supplied £65.5m towards the development
Contracts with France, Germany, Italy and the Netherlands, up to 400 million doses
Serum Institute of India, vaccine alliances, production for poorer countries, 1 billion doses
China, Brazil, Japan and Russia have also expressed interest.

